B. Dayanç Et Al. , "Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen," IASLC 2022 WCLC World Conference on Lung Cancer , vol.17, Vienna, Austria, pp.407, 2022
Dayanç, B. Et Al. 2022. Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen. IASLC 2022 WCLC World Conference on Lung Cancer , (Vienna, Austria), 407.
Dayanç, B., Eriş, S., Çakıroğlu, E., Mazı, F. A., Coşkun, Ö. Ş., Demirci, D., ... Karakülah, G.(2022). Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen . IASLC 2022 WCLC World Conference on Lung Cancer (pp.407). Vienna, Austria
Dayanç, Bengisu Et Al. "Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen," IASLC 2022 WCLC World Conference on Lung Cancer, Vienna, Austria, 2022
Dayanç, Bengisu Et Al. "Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen." IASLC 2022 WCLC World Conference on Lung Cancer , Vienna, Austria, pp.407, 2022
Dayanç, B. Et Al. (2022) . "Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen." IASLC 2022 WCLC World Conference on Lung Cancer , Vienna, Austria, p.407.
@conferencepaper{conferencepaper, author={Bengisu Dayanç Et Al. }, title={Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen}, congress name={IASLC 2022 WCLC World Conference on Lung Cancer}, city={Vienna}, country={Austria}, year={2022}, pages={407} }